Immunomedics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Immunomedics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – IMMU

NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc. for $88.00 per share is fair to Immunomedics shareholders. On behalf of Immunomedics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an Immunomedics shareholder and would l